欧洲儿童癌症长期生存与治愈比例估计(EUROCARE-6):基于人群的研究结果
BACKGROUND: The EUROCARE-5 study revealed disparities in childhood cancer survival among European countries, giving rise to important initiatives across Europe to reduce the gap.…
要点
- 骨肉瘤、尤文肉瘤、伯基特淋巴瘤、非霍奇金淋巴瘤和横纹肌肉瘤的生存率保持稳定。
核心结论
- 欧洲儿童癌症生存率随时间提高,但国家间仍存在差异。
- 通过基于人群的登记数据定期监测儿童癌症生存和估计治愈比例对评估儿科癌症诊疗进展至关重要。
研究设计与样本
- 采用时期分析计算按国家和随时间变化的年龄调整5年生存率差异,覆盖所有癌症合计及主要癌症类型。
- 应用标准混合治愈模型的变体估计儿童癌症患者的治愈比例并估计预测15年生存率。
主要发现
- 几乎全部癌症类型均观察到随时间显著进展;骨肉瘤、尤文肉瘤、伯基特淋巴瘤、非霍奇金淋巴瘤和横纹肌肉瘤的生存率保持稳定。
- 所有癌症合计的年龄调整5年生存率在欧洲国家间仍存在差异,范围为71%(95%CI 60-79)至87%(77-93)。
- 所有儿童癌症合计因非诊断癌症原因导致的年长期死亡率估计约为每1000例患者2例,但视网膜母细胞瘤接近零。
临床怎么用
- 作者认为,通过基于人群的登记数据定期监测儿童癌症生存和估计治愈比例对评估儿科癌症诊疗进展至关重要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The EUROCARE-5 study revealed disparities in childhood cancer survival among European countries, giving rise to important initiatives across Europe to reduce the gap. Extending its representativeness through increased coverage of eastern European countries, the EUROCARE-6 study aimed to update survival progress across countries and years of diagnosis and provide new analytical perspectives on estimates of long-term survival and the cured fraction of patients with childhood cancer. METHODS: In this population-based study, we analysed 135 847 children (aged 0-14 years) diagnosed during 2000-13 and followed up to the end of 2014, recruited from 80 population-based cancer registries in 31 European countries. We calculated age-adjusted 5-year survival differences by country and over time using period analysis, for all cancers combined and for major cancer types. We applied a variant of standard mixture cure models for survival data to estimate the cure fraction of patients by childhood cancer and to estimate projected 15-year survival. FINDINGS: 5-year survival for all childhood cancer combined in Europe in 2010-14 was 81% (95% CI 81-82), showing an increase of three percentage points compared with 2004-06. Significant progress over time was observed for almost all cancers. Survival remained stable for osteosarcomas, Ewing sarcoma, Burkitt lymphoma, non-Hodgkin lymphomas, and rhabdomyoscarcomas. For all cancers combined, inequalities still persisted among European countries (with age-adjusted 5-year survival ranging from 71% [95% CI 60-79] to 87% [77-93]). The 15-year survival projection for all patients with childhood cancer diagnosed in 2010-13 was 78%. We estimated the yearly long-term mortality rate due to causes other than the diagnosed cancer to be around 2 per 1000 patients for all childhood cancer combined, but to approach zero for retinoblastoma. The cure fraction for patients with childhood cancer increased over time from 74% (95% CI 73-75) in 1998-2001 to 80% (79-81) in 2010-13. In the latter cohort, the cure fraction rate ranged from 99% (95% CI 74-100) for retinoblastoma to 60% (58-63) for CNS tumours and reached 90% (95% CI 87-93) for lymphoid leukaemia and 70% (67-73) for acute myeloid leukaemia. INTERPRETATION: Childhood cancer survival is increasing over time in Europe but there are still some differences among countries. Regular monitoring of childhood cancer survival and estimation of the cure fraction through population-based registry data are crucial for evaluating advances in paediatric cancer care. FUNDING: European Commission.
引用
- Botta L, Gatta G, Capocaccia R, et al. Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study. Lancet Oncol. 2022. PMID: 36400102. doi:10.1016/S1470-2045(22)00637-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。